ABSTRACT
ObjectiveTo systematically evaluate the efficacy and safety of Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia， and to provide references for intervention of antipsychotic-induced hyperprolactinemia patients. MethodsEnglish databases （PubMed， Cochrane Library， PsycINFO and Embase） and Chinese databases （CNKI and Wanfang） were systematically searched， with a search time frame of the period from database creation to September 16， 2022. Randomized controlled studies （RCTs） on adjunctive Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia were included. Three investigators independently screened the literatures and extracted data according to PICOS principles and evaluated the quality of including literatures， and the Meta-analysis was performed by using RevMan 5.3. ResultsA total of 3 articles including 256 female schizophrenic patients with hyperprolactinemia were included. Meta-analysis results showed that at the treatment endpoint， the improvement of hyperprolactinemia symptoms reported a significant superiority of the intervention group than the control group （RR=1.73， 95% CI： 1.07~2.79， P˂0.05）. Similarly， the significant superiority of the intervention group than the control group were also found in reducing serum prolactin levels （WMD=-55.17， 95% CI： -68.16~-42.18， P<0.01） and Positive and Negative Syndrome Scale （PANSS） total scores were lower in the intervention group than in the control group （WMD=-7.36， 95% CI： -8.94~-5.77， P<0.01）. ConclusionTianmeng Oral Liquid may help improve clinical efficacy and reduce serum prolactin levels in female schizophrenia patients with hyperprolactinemia. It may improve psychiatric symptoms in female patients with schizophrenia.
ABSTRACT
Objective To observe the effect of Tianmeng Oral Liquid combined with depressant on sexual function of male patient with depression. Methods Male depression outpatients (107 cases) with sexual dysfunction in the processs of treatment in the clinical psychology of the first affiliated hospital of Henan university of Chinese medicine from september 2015 to June 2016 were randomly divided into the control group (55 cases) and treatment group (52 cases). The patients in the control group were po administered with Escitalopram, 10-20 mg/d or Paroxetine, 20-40 mg/d. The patients in the treatment group were po administered with Tianmeng Oral Liquid of 40 mL/d on the basis of the control group. The patients in two groups were treated for four weeks. To evaluate sexual function, depressive symptoms, and sleeping quality by International index of erectile function (IIEF-6) and Conciseness function since the rating scale (BSDSRS-5), Hamilton's depression scale-17 (HAMD-17), and Pittsburgh sleep quality index (PSQI). Results HAMD scores were significantly decreased in both groups after treatment (P < 0.05). HAMD scores of the treatment reduced more obviously than the control group, the difference between the two groups had statistical significance (P < 0.05). Sexual function of the treatment group improved more significantly than the control after treatment (P < 0.05). Sleeping quality of the treatment improved significantly compared with the control after treatment (P < 0.05). Conclusion Tianmeng Oral Liquid combined with depressant Escitalopram, 10-20 mg/d or Paroxetine can increase the sexual function of men with depression effectively and improve depressive symptoms obviously.
ABSTRACT
Objective To investigate the clinical effect of Tianmeng Oral Liquid in treatment of hyperprolactinemia caused by risperidone in female schizophrenia. Methods A total of 90 cases of hyperprolactinemia caused by risperidone in female schizophrenia in Tianjin Anding Hospital from January 2016 to June 2017 were divided into two groups by random number table. Patients in the control group (n = 45) were given ordinary dose of risperidone, while patients in the treatment group were treated with the combination of Tianmeng Oral Liquid and risperidone. After eight weeks of treatment, the level of prolactin (PRL), positive and negative syndrome scale (PANSS), treatment emergent symptom scale (TESS), clinical global impression (CGI), bone mineral density of radius, clinical efficacy, and safety of medication were compared between two groups. Results The level of PRL in treatment group [(80.64 ± 35.12) ng/mL] was lower than control group [(145.46 ± 45.73) ng/mL] (P < 0.05); The scores of positive syndrome, negative syndrome, psychopathology, and total scores in control group were higher than those in treatment group (P < 0.05); The scores of TESS and CGI in treatment group [(2.64 ± 1.25) points, (1.54 ± 0.47) points] were lower than control group [(4.27 ± 3.16) points, (2.39 ± 0.66) points] (P < 0.05); The bone mineral density of radius in treatment group [(-0.27 ± 1.46) SD] was higher than control group [(-0.95 ± 0.86) SD] (P < 0.05); The total effective rate of treatment group [73.33% (33/45)] was higher than control group [53.33% (24/45)] (P < 0.05); There were no abnormal electrocardiogram, heart rate, blood pressure in two groups during treatment. Conclusion Tianmeng Oral Liquid in treatment of hyperprolactinemia caused by risperidone in female schizophrenia is effective, it can decrease the level of PRL, increase bone mineral density of radius, improve irregular menstruation and galactorrhea, and have higher safety without obvious side effects.
ABSTRACT
Objective To observe the clinical effect of Tianmeng Oral Liquid in the treatment of chronic obstructive pulmonary disease and insomnia. Methods Patients (86 cases) with chronic obstructive pulmonary disease and insomnia from February 2013 to February 2015 were randomly divided into control group (43 cases) and experimental group (43 cases). The patients in the control group were administered with conventional therapy. The patients in the treatment group were treated with Tianmeng Oral Liquid on the basis of the control group. Each group was treated for 4 weeks. After treatment, the clinical efficacies and the quality of life were evaluated, and the changes of PSQI scores, total sleep time, sleep efficiency, sleep latency, awakening times, awakening total time, and lung function in two groups were compared. Results After treatment, the clinical efficacies were 79.07% and 93.02% in the control groups and experimental group, respectively, and there were differences between two groups (P < 0.01). After treatment, PSQI scores, awakening times, awakening total time, and respiratory symptoms were significantly reduced, and total sleep time, sleep efficiency, FEV1, and FEV1/FVC were significantly increased, and the difference was significant statistically (P < 0.05). And observational indexes in the experimental group were significantly better than those in the control group (P < 0.05). Conclusion Tianmeng Oral Liquid can improve the sleep quality of patients with the chronic obstructive pulmonary disease and insomnia, also can reduce PSQI scores, which has a certain clinical value.